Tesamorelin: indication-level visceral-adiposity evidence, still unlicensed in the UK

Tesamorelin is the GHRH-receptor analogue with the most mature published human dataset in common research-peptide circulation. That fact is easy to over-read. The completed programmes were run in a defined population — adults with HIV and excess visceral adipose tissue (VAT) — against computed-tomography and imaging endpoints, not against general obesity, athletic body-composition claims, or a UK licence.

This article is a research briefing. It is not a protocol. It does not describe how to obtain, prepare or administer tesamorelin. Tesamorelin is not an MHRA-authorised medicine. Research-use-only framing applies throughout. No consumption or self-administration advice.

1. Chemistry and mechanism

Tesamorelin is a synthetic peptide comprising the 44-amino-acid sequence of human growth-hormone-releasing hormone with an N-terminal trans-3-hexenoic acid modification. The modification increases resistance to dipeptidyl peptidase-4 relative to native GHRH and extends the window in which the analogue can act at pituitary GHRH receptors.

The pharmacology is upstream of growth hormone, not a replacement for it. Binding at somatotroph GHRH receptors stimulates endogenous, pulsatile GH release; circulating IGF-1 rises as a downstream marker. Somatostatin feedback remains intact, which is the usual argument for a more physiological GH envelope than exogenous somatropin. That argument is mechanistic. It is not a safety file, and it is not a licence.

In the HIV-lipodystrophy programmes the consistent body-composition finding was depot-selective: VAT fell; subcutaneous adipose tissue (SAT) was largely preserved; total body weight and BMI moved little. The published effect is not interchangeable with a general weight-loss result.

2. The Phase 3 VAT package

Two multicentre, double-blind, placebo-controlled Phase 3 trials enrolled adults with HIV and excess abdominal fat. Falutz and colleagues reported the first in the New England Journal of Medicine (n = 410, 26 weeks): tesamorelin reduced VAT by 15.2% versus a 5% increase on placebo.[1] The confirmatory trial (n = 396) reported a 10.9% VAT reduction versus 0.6% on placebo, with a smaller waist-circumference change.[2]

The pooled analysis of both programmes (n = 806) is the cleanest single source for magnitude and durability.[3] Over 26 weeks the net VAT reduction relative to placebo was 15.4%. Triglycerides fell (treatment effect approximately −43 mg/dl, −12.3%). Waist circumference fell by a few centimetres, almost entirely accounted for by VAT rather than SAT. Lean mass rose modestly. BMI was essentially unchanged. Among participants who continued tesamorelin through 52 weeks, the net VAT reduction was about 18%; among those switched to placebo after 26 weeks, VAT was regained.[3]

That last point is not a footnote. The VAT effect is treatment-dependent in the published data. It is not a durable remodelling that persists after the analogue is withdrawn.

A later responder analysis linked VAT reduction of at least 8% — the threshold used in the original development programme — to a more favourable triglyceride and glucose-homeostasis profile than non-response.[6] A separate pooled look at participants with elevated baseline transaminases associated clinically significant VAT reduction with improved ALT and AST.[7] Those are secondary and post-hoc readings. They do not convert the analogue into a licensed metabolic medicine in the UK.

3. Liver fat: two randomised trials, still HIV-enriched

Stanley et al. (JAMA, 2014) randomised adults with HIV and abdominal fat accumulation to tesamorelin or placebo for six months (48 treated).[4] VAT fell (treatment effect −42 cm²; net percentage change −16.6%). Hepatic lipid-to-water percentage fell (net treatment effect −2.9 percentage points). SAT did not change significantly. Fasting glucose rose at two weeks and was not different from placebo at six months.[4]

The 2019 Lancet HIV trial moved the question onto NAFLD as an enrolment criterion: 60 adults with HIV and hepatic fat fraction (HFF) of at least 5%, randomised 1:1 for 12 months.[5] Tesamorelin produced a greater HFF reduction than placebo (absolute effect −4.1 percentage points, 95% CI −7.6 to −0.7; relative reduction from baseline −37%). At 12 months, 35% of the tesamorelin arm and 4% of the placebo arm had HFF below 5%. Fibrosis progression was reported as less frequent on tesamorelin in the histology subset; that signal is hypothesis-generating, not a licensed indication.[5]

Both liver-fat trials are HIV-enriched. They do not establish tesamorelin as a general NAFLD intervention, and they have not been the subject of an MHRA or NICE appraisal.

4. What the VAT trials did not show

Several limits are load-bearing.

Not a weight-loss result. Pooled Phase 3 BMI change was negligible.[3] Product labelling in jurisdictions that authorised tesamorelin for HIV-associated excess abdominal fat has stated that the analogue is not indicated for weight reduction in obesity. Citing the HIV-VAT package as if it were an incretin-style obesity programme is a category error.

Cardiovascular outcomes were not the primary endpoint. The 26- and 52-week VAT studies did not determine whether VAT reduction lowers myocardial infarction, stroke or cardiovascular death. Absence of that endpoint is not evidence of cardiovascular harm; it is an evidence gap.

Glucose. Worsening glycaemic control was reported more often on tesamorelin than placebo in the development programme.[1][2][3] Stanley 2014 documented an early fasting-glucose rise that was not significant at six months.[4] The analogue is a GH-axis agonist; GH antagonises insulin action. That is expected pharmacology, not a reason to invent a monitoring protocol here.

IGF-1 and theoretical malignancy risk. Sustained IGF-1 elevation is the mechanistic reason licensed-product labelling in other jurisdictions lists active malignancy as a contraindication. The Phase 3 safety file is measured in hundreds of patients and roughly one to two years of follow-up, not in decade-long cancer-incidence studies.

Population. Almost all of the high-grade human data are in adults with HIV on antiretroviral therapy. Generalisation to adults without HIV, to “somatopause,” or to athletic research-chemical use is not supported at the same grade.

5. Cognition: one controlled trial, not a programme

Baker et al. (Archives of Neurology, 2012) randomised 152 adults aged 55–87 — healthy older adults and adults with amnestic mild cognitive impairment — to daily tesamorelin or placebo for 20 weeks; 137 completed.[8] IGF-1 rose. Executive function improved relative to placebo; a global cognition composite moved favourably; verbal memory showed a weaker signal. Effects were reported in both the healthy and MCI strata.[8]

That is a single 20-week trial, not a Phase 3 cognitive programme, not a licensed indication anywhere, and not a basis for research-chemical cognitive claims. Grade for cognition: limited. Larger confirmatory trials have not established a clinical indication.

6. How tesamorelin sits in the GHRH class

Sermorelin (GHRH 1–29) and CJC-1295 (with or without Drug Affinity Complex) act at the same receptor class. They do not inherit tesamorelin’s Phase 3 VAT file. Tesamorelin does not inherit a UK licence from them either. Ipamorelin and the older GHRPs act at GHS-R1a, not the GHRH receptor; combining the two classes is an experimental design question, not a regulatory status.

Recombinant GH (somatropin) is a licensed UK prescription-only medicine with defined indications and a Summary of Product Characteristics. An endogenous GH pulse after a GHRH analogue is not interchangeable with somatropin-replacement outcomes, and tesamorelin is not a legal substitute for somatropin.

A companion explainer on this site separates GHRH analogues from ghrelin-receptor agonists. This article does not repeat that class map; it asks a narrower question: what tesamorelin’s own trials actually measured, and what they did not licence in the UK.

7. UK regulatory position

Tesamorelin has no UK marketing authorisation. Egrifta, Egrifta SV and Egrifta WR — the pharmaceutical presentations authorised in some other jurisdictions for reducing excess abdominal fat in adults with HIV-associated lipodystrophy — do not appear on the MHRA product register as UK-licensed medicines. No NICE technology appraisal for tesamorelin was identified at the time of writing.[9]

Jurisdictional comparison, stated once: a product licence in another country is not an MHRA authorisation and does not create an NHS commissioning route. Named-patient supply of an unlicensed medicine, where it occurs, is a separate statutory exception under the Human Medicines Regulations 2012. It is not a consumer pathway, and this article does not describe how to use it.

Unlicensed tesamorelin supplied with medicinal claims engages the Human Medicines Regulations 2012 and the Medicines Act 1968. It is not, on current public lists, a Misuse of Drugs Act Schedule 1–5 controlled drug. MHRA 2026 research-peptide labelling guidance applies to research-chemical presentations. WADA prohibits GHRH analogues in sport; that is a sporting rule, not an MHRA schedule.[9][10]

Research-chemical tesamorelin is not the licensed pharmaceutical product. Sequence identity on a certificate of analysis is not GMP equivalence to Egrifta.

8. Honest statements

Permissible on the published record:

Stabilised 44-residue GHRH analogue; pulsatile endogenous GH; IGF-1 rises.
Two Phase 3 VAT trials plus a pooled analysis in adults with HIV and excess abdominal fat: selective VAT reduction of the order of 15% versus placebo at 26 weeks, largely reversed after withdrawal.[1][2][3]
Two randomised liver-fat trials in HIV-associated cohorts: hepatic fat fraction fell.[4][5]
SAT largely preserved; BMI not a primary success metric.
One 20-week cognitive trial in older adults; unreplicated as a development programme.[8]
No UK marketing authorisation; overseas HIV-VAT licences do not transfer.[9]

Not permissible:

Treatment, cure or prevention claims for obesity, NAFLD, cognitive impairment, or any other condition in a UK research-chemical context.
Equivalence to somatropin, to GLP-1 or dual-incretin medicines, or to other GHRH analogues.
Any consumption, reconstitution-for-injection, injection-site or self-administration instruction.
Presenting research-vendor tesamorelin as if it were the licensed pharmaceutical product.

Evidence grade, stated as Peptide Data uses the term: moderate for VAT reduction in the studied HIV-lipodystrophy population on the published Phase 3 record; limited for hepatic fat in HIV-associated NAFLD; limited for cognition; not applicable as a UK-licensed medicine. Grades move only on peer-reviewed human data or a UK regulatory decision.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.